VC
BCAB icon

Vivo Capital’s BioAtla BCAB Stock Holding History

Vivo Capital’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,684
Closed -$908K – 50
2023
Q3 		$908K Sell
10,684
-2,060
-16% -$263K 0.1% 48
2023
Q2 		$1.91M Hold
12,744
– – 0.13% 42
2023
Q1 		$1.71M Hold
12,744
– – 0.12% 40
2022
Q4 		$5.26M Buy
+12,744
New +$5.29M 0.61% 32

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vivo Capital's BCAB Position: Q4 2023 in Review

Vivo Capital sold out of BioAtla (BCAB) in Q4 2023, closing a stake of 10,684 shares — an estimated $908K sold.

Vivo Capital first reported a position in BCAB in Q4 2022 and held it in 4 quarters. The position peaked at $5.26M in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2023.

  • Vivo Capital reported no remaining BioAtla position as of Q4 2023 after selling out during the quarter.
  • Vivo Capital sold 10,684 BioAtla shares in Q4 2023, an estimated $908K.
  • Vivo Capital first reported a position in BioAtla in Q4 2022 and held it in 4 quarters.
  • Vivo Capital's BioAtla position peaked at $5.26M in Q4 2022.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q4 2023.

Based on Vivo Capital's 13F filing for Q4 2023, filed 7 Feb 2024.